Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Black Diamond Therapeutics Inc (NQ: BDTX )

2.345 +0.175 (+8.06%)
Streaming Delayed Price Updated: 3:32 PM EST, Nov 30, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 237,849
Open 2.220
Bid (Size) 2.340 (3)
Ask (Size) 2.350 (17)
Prev. Close 2.170
Today's Range 2.190 - 2.415
52wk Range 1.220 - 6.850
Shares Outstanding 36,213,654
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
Black Diamond Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
From Black Diamond Therapeutics, Inc
Via GlobeNewswire

Performance

YTD
+27.45%
+27.45%
1 Month
+29.56%
+29.56%
3 Month
-32.61%
-32.61%
6 Month
+26.08%
+26.08%
1 Year
+13.29%
+13.29%

More News

Read More
Black Diamond Therapeutics And 2 Other Stocks Under $3 Insiders Are Buying
Via Benzinga
Topics Stocks
Exposures US Equities
Black Diamond Therapeutics Presents Dose Escalation Data Demonstrating Durable Responses in Patients with NSCLC from Phase 1 Trial of BDTX-1535
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
What 6 Analyst Ratings Have To Say About Black Diamond Therapeutic
Via Benzinga
Where Black Diamond Therapeutic Stands With Analysts
Via Benzinga
Black Diamond Therapeutics to Present Preclinical and Clinical Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Black Diamond Therapeutics Announces CEO Transition
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
Black Diamond Therapeutics Announces First Patients Dosed in Phase 1 Clinical Trial Expansion Cohorts Evaluating BDTX-1535 in Patients with Intrinsic Driver and Acquired Resistance EGFR Mutation Positive Non-Small Cell Lung Cancer
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
Black Diamond Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For July 14, 2023
Via Benzinga
$4.7M Bet On Black Diamond Therapeutics? Check Out These 3 Stocks Insiders Are Buying
Via Benzinga
Nanobiotix, NanoString Technologies And Other Big Stocks Moving Higher In Monday's Pre-Market Session
Via Benzinga
Why Icahn Enterprises Shares Are Trading Higher By 18%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
$1M Bet On Children's Place? Check Out These 3 Stocks Insiders Are Buying
Via Benzinga
$5M Bet On This Biotechnology Stock? Check Out These 3 Stocks Insiders Are Buying
Via Benzinga
Genuine Monotherapy Approach In EGFRm NSCLC: Analyst Upgrades Switches To Buy On Black Diamond Therapeutics
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 30, 2023
Via Benzinga
$1.5M Bet On ONEOK? Check Out These 3 Stocks Insiders Are Buying
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Via InvestorPlace
Black Diamond Therapeutics Announces Pricing of Public Offering of Common Stock
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
Why Shares of Black Diamond Therapeutics Skyrocketed This Week
Via The Motley Fool
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.